Researchers continue to tweak breast cancer risk-prediction tests in an effort to improve the accuracy. (Cancer Research UK, Genetics in Medicine)
NICE, the British healthcare cost-effectiveness agency gave a thumbs-up to the CDK4/6 inhibitor abemaciclib (Verzenio), in combination with an aromatase inhibitor for advanced/metastatic HR+/HER2- breast cancer.
A survey of oncologists showed a lack of awareness about the health needs of LGBTQ patients and a desire to be better educated about their needs. (NYU Langone Medical Center, Moffitt Cancer Center)
Acupressure relieved several types of symptoms associated with breast cancer treatment. (Michigan Medicine)
Support for personalized treatment plans to improve outcomes in kidney cancer. (Radiological Society of North America)
Could grocery receipts be carcinogenic? (Metro UK)
Whereas contaminated valsartan has gotten a lot of bad press over a potential cancer risk, a related antihypertensive drug — losartan — may improve the effectiveness of chemotherapy for ovarian cancer. (Massachusetts General Hospital)
Another drug originally developed for high blood pressure blocked a key step in the formation of cancer metastases in animal models. (Cancer Cell, University of Pennsylvania)
Isofol Medical reported that almost half of patients with metastatic colorectal cancer had tumor shrinkage when treated with the investigational drug arfolitixorin — a metabolite of antifolates — plus chemotherapy.
James Watson, PhD, who along with Francis Crick, PhD, won a Nobel Prize for discovering the double-helix structure of DNA, lost his honorary status at the prestigious laboratory he led for 25 years, after making racist remarks on a video documentary. (CNN)
Source: MedicalNewsToday.com
